Status:

COMPLETED

Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer

Lead Sponsor:

Sanofi

Collaborating Sponsors:

Regeneron Pharmaceuticals

Conditions:

Colorectal Neoplasms

Neoplasm Metastasis

Eligibility:

All Genders

20+ years

Phase:

PHASE1

Brief Summary

The primary objective is to determine the dose of aflibercept to be further studied in combination with irinotecan/5-fluorouracil/isovorin (FOLFIRI) in Japanese patients with metastatic colorectal can...

Eligibility Criteria

Inclusion

  • Patients with histologically or cytologically proven malignant tumor of the colon or rectum which is metastatic and inoperable.
  • Patients must have received at least one prior line of treatment with any standard of care, who have failed the treatment, or who have not been eligible for standard of care for safety reasons.

Exclusion

  • Treatment with chemotherapy, hormone therapy, radiotherapy, surgery, blood products, or any investigational agent within 28 days.
  • ECOG Performance Status\>1
  • Anticipated need for a major surgical procedure or radiation therapy during the study.
  • Uncontrolled malignant ascites.
  • History of brain metastases, spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease on screening CT or MRI scan.
  • Pregnant or breast-feeding women.
  • Uncontrolled hypertension
  • Patients who have previously been treated with aflibercept
  • History of abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28 days.
  • History of hypersensitivity to any recombinant proteins, irinotecan, fluoropyrimidine or isovorin.
  • Known dihydropyrimidine dehydrogenase deficiency.
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Key Trial Info

Start Date :

June 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2012

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT00921661

Start Date

June 1 2009

End Date

June 1 2012

Last Update

November 9 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sanofi-Aventis Administrative Office

Tokyo, Japan